The research grants program administered by the Grants and Contracts Operations Branch (GCOB) supports all aspects of preclinical anticancer drug discovery and treatment strategies, including drug design, selective targeting of therapeutic agents, development of new preclinical models for drug discovery, and understanding, preventing and overcoming drug resistance. Applications are accepted in the following drug research categories: synthesis and chemistry, natural products, screening and experimental therapeutics, pharmacology, toxicology, biochemistry and mechanism of action. Grant applications which include support of clinical trials and/or studies of patient outcome are not appropriate for this program; for these, the applicant is referred to the Cancer Therapy Evaluation Program.
GCOB resides in a unique situation in relation to the extramural grant community and the drug discovery/development activities of the Developmental Therapeutics Program (DTP). Through management of a large grant and cooperative agreement portfolio, GCOB staff maintains extensive interactions with the external research community and can provide advice to foster the drug discovery mandate of the DTP. Such activities include assisting grantees to access the NCI drug and Natural Product repositories, inviting scientists to participate in a DTP seminar series, and arranging for compound testing and identification of molecular targets in the 60 cell line screen. Staff can advise grantees regarding availability of NCI resources for development of their agents to clinical trial.
Applicants and potential applicants are encouraged to discuss any questions they might have with Dr. Wolpert or the Program Directors either by phone or e-mail. The areas of responsibility of the GCOB staff is indicated below to help you select the staff member who best represents the subject material of your research:
|
Dr. Arya: |
molecular target identification and characterization; stem cells; oncogenes; tumor suppressor genes; genetic mutation; epigenetic alterations; gene therapy (excluding lentiviruses); viral therapy, si/shRNA, miRNA, piRNA; gene transfer; vector design; DNA synthesis and repair; gene expression and transcription; translation; RNA processing; cell cycle; apoptosis pathway; autophagy; polyamines; telomerase; topoisomerases |
|
Dr. Forry-Schaudies: |
folate biochemistry; drug resistance, including multidrug resistance; signaling; growth factor receptors; extracellular matrix; non-mammalian organisms; angiogenesis; metastasis; adhesion; motility, invasion; gene therapy, including lentiviral vectors; combination chemotherapy |
|
Dr. Fu: |
drug formulations; drug delivery; Nanotechnology in drug delivery (nanoparticles); liposomes; biosynthesis/bioengineering; natural products isolation, characterization and mechanism of action (Didemnins, camptothecins, bryostatins, rapamycin, etoposide, taxol, etc); marine, plants, animals; targeted therapies; genetically engineered organisms for production; tubulin interacting agents |
|
Dr. Lees: |
chemistry; synthetic and structural chemistry; NMR; x-ray crystallography; drug design; medicinal chemistry; total synthesis; library synthesis (combinatorial/parallel chemistry); computer modeling; structure-based drug design; chemical biology; bioorganic and bioinorganic chemistry |
|
Dr. Song: |
drug safety and efficacy biomarkers; toxicogenomics; pharmacogenetics; pharmacogenomics; proteomics; metabolomics; molecular profiling; bioinformatics, systems biology; individualized therapies; predictive ADME/Tox; toxicology; pharmacology; pharmacokinetics; pharmacodynamics; drug metabolism; assay technologies for drug discovery and development; drug safety/toxicity models; drug efficacy models (transgenics, knockouts, etc.); clinically relevant preclinical models; target validation; mechanisms of drug action; exploratory IND studies, translational research |
|
Dr. Wolpert: |
biological studies involving; metal complexes; host-tumor interactions; mechanistic drug studies on standard agents (folates, 5-FU, cisplatin, etc.); Other |
NIH Research Grant Funding Mechanisms:
-
Supplements for ongoing grants
Minorities
Persons with Disabilities
Reentry into Research -
Exploratory/Developmental Grant (R21) - This award is for pilot projects or feasibility studies to support creative, novel, high-risk/high payoff research. An R21 can be submitted only in response to a Request for Application (RFA) or Program Announcement (PA).
-
Exploratory/Developmental Grant Phase II (R33) - This award is to give continued support for innovative exploratory research initiated under the R21 mechanism. An R33 can be submitted only in response to a Request for Application (RFA) or Program Announcement (PA).
-
NCI Small Business Funding Opportunities
Tips for SBIR Phase I and SBIR Phase II Applicants for the Developmental Therapeutics Program, NCI
-
Shannon Award (R55) - Notice-NCI-Sponsored Year-Round Shannon Award Program, NIH Guide 3/29/96
GCOB Program Announcements
GCOB Request for Applications
Non-Grant-Supported Special Initiatives:
-
Rapid Access to Intervention Development (RAID) Two receipt dates per year: February 1 and August.1.
GCOB works with DCTD in supporting this special initiative to aid the development of innovative anti-cancer agents to clinical trial. Current guidelines can be found at the Developmental Therapeutics Program website
Original NIH Guide Announcement, May 11, 1998
Addendum: